PURPOSE: To examine the prevalence of macular telangiectasia type 2 and lesions characterizing it. DESIGN: Population-based cohort study. METHODS: setting: City and township of Beaver Dam, 1988-1990. study population: A total of 4790 people 43-86 years of age. observation procedure(s): Grading from stereoscopic fundus photographs to measure macular telangiectasia type 2. main outcome measure: Prevalent macular telangiectasia type 2. RESULTS: Macular telangiectasia type 2 was present at baseline in 0.1% of the population (95% confidence interval [CI] 0.09, 0.1). The frequencies of loss of retinal transparency, crystals in the inner retinal layers, blunted retinal vessels, localized intraretinal pigment migration in the juxtafoveolar region, and presence of yellow deposits and lamellar holes in the foveal area in those without macular telangiectasia type 2 varied from 0.06% for retinal telangiectatic vessels to 1.2% for lamellar holes. Smoking was associated with pigment clumping (odds ratio [OR] per pack year 1.02; 95% CI 1.00, 1.03; P = .02), retinal pigment epithelial (RPE) depigmentation (OR 1.02 per pack year; 95%CI 1.00, 1.04; P = .02), loss of transparency (OR 1.02 per pack year; 95% CI 1.00, 1.03; P = .008), and the presence of a yellow spot in the fovea (OR 2.24 current vs past or never smoker; 95% CI 1.29, 3.89; P = .004), but not with presence of macular telangiectasia type 2 (OR 2.72; 95% CI 0.45, 16.28; P = .27). CONCLUSIONS: The prevalence of macular telangiectasia type 2 (0.1%) is higher than previously thought. These data are useful in estimating the burden of this condition in the population. The role of smoking in the development of macular telangiectasia type 2 requires further study. 2010 Elsevier Inc. All rights reserved.
PURPOSE: To examine the prevalence of macular telangiectasia type 2 and lesions characterizing it. DESIGN: Population-based cohort study. METHODS: setting: City and township of Beaver Dam, 1988-1990. study population: A total of 4790 people 43-86 years of age. observation procedure(s): Grading from stereoscopic fundus photographs to measure macular telangiectasia type 2. main outcome measure: Prevalent macular telangiectasia type 2. RESULTS:Macular telangiectasia type 2 was present at baseline in 0.1% of the population (95% confidence interval [CI] 0.09, 0.1). The frequencies of loss of retinal transparency, crystals in the inner retinal layers, blunted retinal vessels, localized intraretinal pigment migration in the juxtafoveolar region, and presence of yellow deposits and lamellar holes in the foveal area in those without macular telangiectasia type 2 varied from 0.06% for retinal telangiectatic vessels to 1.2% for lamellar holes. Smoking was associated with pigment clumping (odds ratio [OR] per pack year 1.02; 95% CI 1.00, 1.03; P = .02), retinal pigment epithelial (RPE) depigmentation (OR 1.02 per pack year; 95%CI 1.00, 1.04; P = .02), loss of transparency (OR 1.02 per pack year; 95% CI 1.00, 1.03; P = .008), and the presence of a yellow spot in the fovea (OR 2.24 current vs past or never smoker; 95% CI 1.29, 3.89; P = .004), but not with presence of macular telangiectasia type 2 (OR 2.72; 95% CI 0.45, 16.28; P = .27). CONCLUSIONS: The prevalence of macular telangiectasia type 2 (0.1%) is higher than previously thought. These data are useful in estimating the burden of this condition in the population. The role of smoking in the development of macular telangiectasia type 2 requires further study. 2010 Elsevier Inc. All rights reserved.
Authors: Lelia A Paunescu; Tony H Ko; Jay S Duker; Annie Chan; Wolfgang Drexler; Joel S Schuman; James G Fujimoto Journal: Ophthalmology Date: 2005-12-15 Impact factor: 12.079
Authors: Thomas A Albini; Matthew S Benz; Robert E Coffee; Andrew C Westfall; Rohit R Lakhanpal; Alice R McPherson; Eric R Holz Journal: Ophthalmic Surg Lasers Imaging Date: 2006 Mar-Apr
Authors: Jason N Crosson; Thomas A Swain; Mark E Clark; Carrie E Huisingh; Gerald McGwin; Cynthia Owsley; Christine A Curcio Journal: Ophthalmol Retina Date: 2019-03-30
Authors: Thomas S Scerri; Anna Quaglieri; Carolyn Cai; Jana Zernant; Nori Matsunami; Lisa Baird; Lea Scheppke; Roberto Bonelli; Lawrence A Yannuzzi; Martin Friedlander; Catherine A Egan; Marcus Fruttiger; Mark Leppert; Rando Allikmets; Melanie Bahlo Journal: Nat Genet Date: 2017-02-27 Impact factor: 38.330
Authors: Qinyun Wang; William S Tuten; Brandon J Lujan; Jennifer Holland; Paul S Bernstein; Steven D Schwartz; Jacque L Duncan; Austin Roorda Journal: Invest Ophthalmol Vis Sci Date: 2015-01-13 Impact factor: 4.799
Authors: Annal D Meleth; Brian C Toy; Divya Nigam; Elvira Agrón; Robert P Murphy; Emily Y Chew; Wai T Wong Journal: Retina Date: 2013-04 Impact factor: 4.256
Authors: Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl Journal: Prog Retin Eye Res Date: 2012-12-03 Impact factor: 21.198
Authors: Qinqin Zhang; Ruikang K Wang; Chieh-Li Chen; Andrew D Legarreta; Mary K Durbin; Lin An; Utkarsh Sharma; Paul F Stetson; John E Legarreta; Luiz Roisman; Giovanni Gregori; Philip J Rosenfeld Journal: Retina Date: 2015-11 Impact factor: 4.256
Authors: Marin L Gantner; Kevin Eade; Martina Wallace; Michal K Handzlik; Regis Fallon; Jennifer Trombley; Roberto Bonelli; Sarah Giles; Sarah Harkins-Perry; Tjebo F C Heeren; Lydia Sauer; Yoichiro Ideguchi; Michelle Baldini; Lea Scheppke; Michael I Dorrell; Maki Kitano; Barbara J Hart; Carolyn Cai; Takayuki Nagasaki; Mehmet G Badur; Mali Okada; Sasha M Woods; Catherine Egan; Mark Gillies; Robyn Guymer; Florian Eichler; Melanie Bahlo; Marcus Fruttiger; Rando Allikmets; Paul S Bernstein; Christian M Metallo; Martin Friedlander Journal: N Engl J Med Date: 2019-09-11 Impact factor: 91.245